Homocysteine

Critical Reviews in Clinical Laboratory Sciences

Volumn 36, Issue 4, 1999, Pages 365-406

  Langman, Loralie J ^a   Cole, David E C ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cardiovascular disease; Genetics; Homocysteine; Metabolism

Indexed keywords

AMINO ACID; CREATININE; CYANOCOBALAMIN; CYSTEINE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PYRIDOXINE; SERUM ALBUMIN; URATE; VITAMIN;

BLOOD LEVEL; CORONARY ARTERY DISEASE; DEMETHYLATION; DIAGNOSTIC ACCURACY; DIETARY INTAKE; DRUG USE; GENETIC VARIABILITY; HORMONE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FUNCTION; METABOLISM; NEURAL TUBE DEFECT; NUTRIENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM; VEIN OCCLUSION;

AMINO ACID METABOLISM, INBORN ERRORS; FEMALE; HOMOCYSTEINE; HUMANS; MALE; NEURAL TUBE DEFECTS; VASCULAR DISEASES;

EID: 0032847921     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408369991239231     Document Type: Review

References (243)

1. Mudd SH, Levy HL Skovby F. Disorders of Transsulfuration, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular bases of inherited disease. Pp. 1279-1327. New York, McGraw-Hill Inc., 1995.
2. Skovby F. Homocystinuria. Clinical, biochemical and genetic aspects of cystathionine β-synthase and its deficiency in man. Acta Paediatr Scand 1985; (Suppl. 321): 7-21.
3. Boers GHJ, Fowler B, Smals AGH, et al. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985; 69: 164-169.
4. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathioninc β-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
5. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-359.
6. Blundell G, Rose FA Tudball N. Homocysteine induced endothelial cell toxicity and its protection, Biochem Soc Trans 1994; 22: 341S.
7. Clarke R, Naughten E, Cahalane S, et al. The role of free radicals as mediators of endothelial cell injury in hyperhomocysteinemia. Irish J Med Sci 1992; 161: 561-564.
8. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine; a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
9. Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146-153.
10. Malinow MR, Nieto FJ, Szklo M, et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87: 1107-1113.
11. McCully KS. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 1993; 23: 477-493.
12. Wilcken DEL, Dudman NP. Homocystinuria and atherosclerosis. Molecular genetics of coronary artery disease: Processes in atherosclerosis. Pp. 311-324. Basel: Karger, 1992.
13. Finkelstein JD, Martin JJ. Methionine metabolism in mammals: adaptation to methionine excess. J Biol Chem 1986; 261: 1582-1587.
14. Rosenblatt DS. Inherited disorders of folate transport and metabolism. The metabolic and molecular bases of inherited disease. Pp. 3111-3128, New York: McGraw-Hill, 1995.
15. Mayer EL, Jacobsen DW Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
16. Wilcken DEL, Wilcken B, Dudman NPB, et al. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983; 309: 448-453.
17. Nordstrom M, Kjellstrom T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis 1992; 94:213-221.
18. Simon DI, Stamler JS, Jaraki O, et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 1993; 13: 791-799.
19. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.
20. House JD, Brosnan ME Brosnan JT. Characterization of homocysteine metabolism in the rat kidney. Biochem J 1997; 328: 287-292.
21. Ibels LS, Stewart JH, Mahony JF, et al. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. A study of the incidence of arterial disease and of the prevalence of msk factors implicated in the pathogenesis of arteriosclerosis. Q J Med 1977; 46: 197-214.
22. Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in the yeast Saccharomyces cerevisiae. EMBO J 1991; 10: 593-598.
23. Dudman NP, Hicks C, Lynch JF, et al. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb 1991; 11: 663-670.
24. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995; 41: 340-342.
25. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen, J Clin Invest 1993; 91: 308-318.
26. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
27. Folbergrova J. NMDA and not non-NMDA receptor antagonists are protective against seizures induced by homocysteine in neonatal rats, Exp Neurol 1994; 130: 344-350.
28. Lipton SA, Kim W-K, Choi Y-B, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997; 94: 5923-5928.
29. Refsum H, Guttormsen AB, Fiskerstrand T, et al. Hyperhomocysteinemia in terms of steady-state kinetics. Eur J Pediatr 1998; 157(Suppl. 2): S45-S49.
30. Welch GN, Upchurch GRJ Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract (Off Ed) 1997; 32: 81-92.
31. Pastore A, Massoud R, Motti C, et al. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine. Clin Chem 1998; 44: 825-832.
32. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380-25385.
33. Jakubowski H. Metabolism of homocysteine thiolactone in human, cell cultures: Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272: 1935-1942.
34. Naruszewicz M, Mirkiewicz E, Olszewski AJ, et al. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 1994; 4: 70-77.
35. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389.
36. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993; 14: 683-693.
37. Harpel PC, Chang VT Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
38. Liu G, Nellaiappan K Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. J Biol Chem 1997; 272: 32370-32377.
39. Perna AF, Ingrosso D, Galletti P, et al. Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 1996; 50: 358-366.
40. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157(Suppl. 2): S40-S44.
41. Koch HG, Goebeler M, Marquardt T, et al. The redox status of aminothiols as a clue to homocysteine-induced vascular damage? Eur J Pediatr 1998; 157(Suppl. 2): S102-6.
42. Hultberg B, Andersson A Isaksson A. Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture line (human histiocytic cell line U-937). Biochim Biophys Acta 1995; 1269: 6-12.
43. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 1998; 274: C396-C405.
44. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
45. Stehouwer CD, Jakobs C. Abnormalities of vascular function in hyperhomocysteinaemia: relationship to atherothrombotic disease. Eur J Pediatr 1998; 157(Suppl. 2): S107-11.
46. Upchurch Jr. GR, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017.
47. Hayashi T, Honda G Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-2936.
48. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914.
49. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683-689.
50. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. J Clin Invest 1993; 92: 1400-1406.
51. Wall RT, Harlan JM, Harker LA, et al. Homocyteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
52. Kang SS, Wong PW Curley K. The effect of D-penicillamine on protein-bound homocyst(e)ine in homocysteinurics. Pediatr Res 1982; 16: 370-372.
53. Lubec B, Fang-Kircher S, Lubec T, et al. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996; 1315: 159-162.
54. Bellamy MF, McDowell IFW. Putative mechanisms for vascular damage by homocysteine. J Inher Metab Dis 1997; 20; 307-315.
55. Dalton ML, Gadson PF Jr, Wrenn RW, et al. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-711.
56. Lubec B, Arbeiter K, Hoeger H, et al. Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost 1996; 75: 542-545.
57. Lubec B, Labudova O, Hoeger H, et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996; 94: 2620-2625.
58. Fritzer-Szekeres M, Blom HJ, Boers GH, et al. Growth promotion by homocysteine but not by homocysteic acid: a role for excessive growth in homocystinuria or proliferation in hyperhomocysteinemia? Biochim Biophys Acta 1998; 1407: 1-6.
59. Jaffe EH, Garcia Y. Excitatory sulfur-containing amino acid-induced release of [3H]GABA from rat olfactory bulb. Neurochem Res 1997; 22: 1477-1484.
60. Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. JAMA 1995; 274: 1526-1533.
61. Kozich V, Kraus E, de Franchis R, et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine β-synthase alleles at the molecular level. Hum Mol Genet 1995; 4: 623-629.
62. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
63. Kuo L, Davis MJ, Cannon MS, et al. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res 1992; 70: 465-476.
64. Sebastio G, Sperandeo MP, Panico M, et al. The molecular basis of homocystinuria due to cystathionine β-synthase deficiency in Italian families, and report of four novel mutations. Am J Med 1995; 56: 1324-1333.
65. Tsai MY, Bignell M, Schwichtenberg K, et al. High prevalence of a mutation in the cystathionine β-synthase gene. Am J Hum Genet 1996; 59: 1262-1267.
66. de Franchis R, Buoninconti A, Fermo I, et al. Increased thrombotic risk for patients with associated 844ins68 mutation of the cystathionine beta-synthase (CBS) gene and the 677C->T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. Am J Hum Genet 1998; 63(Suppl. 1): A210 (Abstract).
67. Chen LH, Liu M-L, Hwang H-Y, et al. Human methionine synthase: cDNA cloning, gene localization, and expression. J Biol Chem 1997; 272: 3628-3634.
68. Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867-1874.
69. Li YN, Gulati S, Baker PJ, et al. Cloning, mapping and RNA analysis of the human methionine synthase gene. Hum Mol Genet 1996; 5: 1851-1858.
70. Goulding CW, Postigo D Matthews RG. Cobalamin-dependent methionine synthase is a modular protein with distinct regions for binding homocysteine, methyltetrahydrofolate, cobalamin, and adenosylmethionine. Biochemistry 1997; 36: 8082-8091.
71. Visy JM, Le Coz P, Chadefaux B, et al. Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency revealed by stroke in adult siblings. Neurology 1991; 41: 1313-1315.
72. Goyette P, Frosst P, Rosenblatt DS, et al. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlation in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-1059.
73. Kang SS, Wong PW, Bock HG, et al. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991; 48: 546-551.
74. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nature Genet 1994; 7: 195-200.
75. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996; 19: 171-178.
76. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10: 111-113.
77. Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
78. Engbersen AM, Franken DG, Boers GH, et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-150.
79. Arruda VR, Siqueira LH, Goncalves MS, et al. Prevalence of the mutation C677 → T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet 1998; 78: 332-335.
80. Franco RF, Araujo AG, Guerreiro JF, et al. Analysis of the 677 C → T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79: 119-121.
81. Gregg J, Bando JM, Crandall BF, et al. Frequencies of two common polymorphisms in the methylenetetrahydrofolate reductase gene in four different ethnic American populations. Am J Hum Genet 1998; 63(Suppl. 1): A213(Abstract).
82. Pepe G, Camacho VO, Giusti B, et al. Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. Am J Hum Genet 1998; 63: 917-920.
83. Stevenson RE, Schwartz CE, Du Y-Z, et al. Differences in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet 1997; 60: 229-230.
84. Harmon DL, Woodside JV, Yarnell JWG, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med 1996; 89: 571-577.
85. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 569-573.
86. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHPR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-2036.
87. Hegele RA, Tully C, Young TK, et al. V677 mutation of methylenetetrahydrofolate reductase and cardiovascular disease in Canadian Inuit, Lancet 1997; 349: 1221-1222.
88. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, et al. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-23.
89. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-3078.
90. van der Put NMJ, Steegers-Thenissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1071.
91. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
92. Dunn J, Title LM, Bata I, et al. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early-onset coronary artery disease. Clin Biochem 1998; 31: 95-100.
93. Fermo I, Vigano' D'Angelo S, Paroni R, et al. A: Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.
94. Scott JM, Weir DG. Homocysteine and cardiovascular disease. Q J Med 1996; 89: 561-563.
95. van der Put NM, Eskes TK Blom HJ. Is the common 677C → T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Q J Med 1997; 90: 111-115.
96. van der Put NMJ, van den Heuvel LP, Steegers-Theunissen RPM, et al. Decreased methylene tetrahydrofolate reductase activity due to the 677C-T mutation in families with spina bifida offspring. J Mol Med 1996; 74: 691-694.
97. Makowski GS, Hopper SM. Measurement of maternal folate status and risk of neural tube defects. Clin Chem 1997; 43: 185-186.
98. Rosenquist TH, Ratashak SA Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996; 93: 15227-15232.
99. Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
100. Langman U, Wong BYL, Boggis C, et al. The prevalence and linkage disequilibrium of three methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms varies in different ethnic groups. J Vasc Res 1998; 35(Suppl. 3): 4(Abstract).
101. Blom HJ. Determinants of plasma homocysteine. Am J Clin Nutr 1998; 67: 188-189.
102. Smithells RW, Seller MJ, Harris R, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1: 1027-1031.
103. MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991; 338: 131-137.
104. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-1835.
105. Werler MM, Shapiro S Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269: 1257-1261.
106. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
107. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.
108. Steegers-Theunissen RP Smithells RW Eskes TK. Update of new risk factors and prevention of neural-tube defects. Obstet Gynecol Survey 1993; 48: 287-293.
109. Burke G, Robinson K, Refsum H, et al. Intrauterine growth retardation, perinatal death, and maternal homocysteine levels. N Engl J Med 1992; 326: 69-70.
110. Wouters MG, Boers GH, Blom HJ, et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993; 60: 820-825.
111. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048.
112. Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Hyperhomocysteinaemia and recurrent spontaneous abortion or abruptio placentae. Lancet 1992; 339: 1122-1123.
113. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345: 149-151.
114. Steegers-Theunissen RP, Boers GH, Trijbels FJ, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994; 43: 1475-1480.
115. Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995; 172: 1436-1441.
116. van der Put KM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
117. Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem 1995; 41: 173-176.
118. Malinow MR. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81: 2004-2006.
119. Frohlich JJ. Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: Assessment and treatment. Can J Cardiol 1995; 11(Suppl. C): 18C-23C.
120. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617.
121. Fortin L-J, Genest J Jr. Measurement of homocyst(e)ine in the prediction of arteriosclerosis. Clin Biochem 1995; 28: 155-162.
122. Nygård O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
123. 6 and cardiovascular disease. JAMA 1998; 279: 292-293.
124. Anand SS, Yusuf S. Risk factors for cardiovascular disease in Canadians of South Asian and European origin: a pilot study of the Study of Heart Assessment and Risk in Ethnic Groups (SHARE). Clin Invest Med 1997; 20: 204-210.
125. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
126. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
127. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277: 1775-1781.
128. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.
129. Falcon CR, Cattaneo M, Panzeri D, et al. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083.
130. Brattstrom L, Tengborn L, Lagerstedt C, et al. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57.
131. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
132. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2106.
133. Mansoor MA, Svardal AM Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992; 200: 218-229.
134. Mansoor MA, Guttormsen AB, Fiskerstrand T, et al. Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration. Clin Chem 1993; 39: 980-985.
135. Andersson A, Isaksson A, Brattstrom L, et al. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 1993; 39: 1590-1597.
136. Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-1779.
137. Refsum H, Ueland PM Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem 1989; 35: 1921-1927.
138. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549-554.
139. Ubbink JB, Vermaak WJH Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-446.
140. Cornwell PE, Morgan SL Vaughn WH. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma. J Chromatogr 1993; 617: 136-139.
141. Cole DEC, Lehotay DC Evrovski J. Simplified simultaneous assay of total homocysteine and methionine by HPLC and pulsed integrated amperometry. Clin Chem 1998; 44: 188-190.
142. Gilfix BM, Blank DW Rosenblatt DS. Novel reductant for determination of total plasma homocysteine. Clin Chem 1997; 43: 687-688.
143. Frantzen F, Faaren AL, Alfheim I, et al. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-316.
144. Malinow MR, Axthelm MK, Meredith MJ, et al. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med 1994; 123: 421-429.
145. Andersson A, Isaksson A Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 1992; 38: 1311-1315.
146. Willems HPJ, Bos GMJ, Gerrits WBJ, et al. Acidic citrate stabilizes blood samples for assay of total homocysteine. Clin Chem 1998; 44: 342-345.
147. Abeles RH, Tashjian AH Jr Fish S. The mechanism of inactivation of s-adenosylhomocysteinase by 2′-deoxyadenosine. Biochem Biophys Res Commun 1980; 95: 612-617.
148. Helland S, Ueland PM. Inactivation of s-adenosylhomocysteine hydrolase by 9-β-D-arabinofuranosyladenine in intact cells. Cancer Res 1982; 42: 1130-1136.
149. Helland S, Ueland PM. Effect of 2′-deoxycoformycin infusion on s-adenosylhomocysteine hydrolase and the amount of s-adenosylhomocysteine and related compounds in tissues of mice. Cancer Res 1983; 43: 4142-4147.
150. Moller J, Rasmussen K. Homocysteine in plasma: stabilization of blood samples with fluoride. Clin Chem 1995; 41: 758-759.
151. Hughes MP, Carlson TH McLaughlin MK, et al. Addition of sodium fluoride to whole blood does not stabilize plasma homocysteine but produces dilution effects on plasma constituents and hematocrit. Clin Chem 1998; 44: 2204-2206.
152. Probst R, Brandl R, Blumke M, et al. Stabilization of homocysteine concentration in whole blood. Clin Chem 1998; 44: 1567-1569.
153. Nilsson K, Gustafson L, Faldt R, et al. Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest 1994; 24: 600-606.
154. Boers GH, Smals AG, Trijbels FJ, et al. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971-1976.
155. Andersson A, Brattstrom L, Israelsson B, et al. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invent 1992; 22: 79-87.
156. Brattstrom L, Lindgren A, Israelsson B, et al. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994; 236: 633-641.
157. Jacobsen DW. Determinants of hyperhomocysteinemia: a matter of nature and nurture. Am J Clin Nutr 1996; 64: 641-642.
158. Van der Mooren MJ, Wouters MGAJ, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733-736.
159. Wouters MGAJ, Moorrees MTEC, Van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801-805.
160. Steegers-Theunissen RPM, Wathen NC, Eskes TKAB, et al. Maternal and fetal levels of methionine and homocysteine in early pregnancy. Br J Obstet Gynaecol 1997; 104: 20-24.
161. Andersson A, Hultberg B, Brattstrom L, et al. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992; 30: 377-379.
162. Ubbink JB, Vermaak WJ, van der Merwe A, et al. The effect of Wood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta 1992; 207: 119-128.
163. Guttormsen AB, Schneede J, Fiskerstrand T, et al. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994; 124: 1934-1941.
164. Ubbink JB. Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr Rev 1994; 52: 383-393.
165. Kushi LH, Lenart EB Willett WC. Health implications of Mediterranean diets in light of contemporary knowledge. I. Plant foods and dairy products. Am J Clin Nutr 1995; 61: 1407S-1415S.
166. Nygård O, Refsum H, Ueland PM, et al. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263-270.
167. Nygård O, Refsum H, Ueland PM, et al. Coffee consumption and plasma total homocysteine: the Hordaland homocysteine study. Am J Clin Nutr 1997; 65: 136-143.
168. Cravo ML, Gloria LM, Selhub J, et al. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 1996; 63: 220-224.
169. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
170. Glueck CJ, Shaw P, Lang JE, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-136.
171. Frauscher G, Kamaukhova E, Muehl A, et al. Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid-additional mechanisms in homocysteine induced endothelial damage? Life Sci 1995; 57: 813-817.
172. Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. JAMA 1993; 270: 2726-2727.
173. Ubbink JB, Becker PJ, Vermaak WJH, et al. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995; 41: 1033-1037.
174. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11.
175. Joosten E, Pelemans W, Devos P, et al. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum cobalamin. Eur J Haematol 1993; 51: 25-30.
176. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteine in an elderly population. JAMA 1993; 270: 2693-2698.
177. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992; 40: 1197-1204.
178. Naurath HJ, Joosten E, Reizler R, et al. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346: 85-89.
179. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-948.
180. Savage DG, Lindenbaum J, Stabler SP, et al. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994; 96: 239-246.
181. Chadefaux B, Cooper BA, Gilfix BM, et al. Homocysteine: relationship to serum cobalamin, serum folate, erythrocyte folate, and lobation of neutrophils. Clin Invest Med 1994; 17: 540-550.
182. Carmel R. Pernicious anemia: the expected findings of very low serum cobalamin levels, anemia, and macrocytosis are often lacking. Arch Intern Med 1988; 148: 1712-1714.
183. Beck WS. Diagnosis of megaloblastic anemia. Annu Rev Med 1991; 42: 311-322.
184. Anonymous. Guidelines on the investigation and diagnosis of cobalamin and folate deficiencies, A publication of the British Committee for Standards in Haematology. BCSH General Haematology Task Force. Clin Lab Haematol 1994; 16: 101-115.
185. Curtis D, Sparrow R, Brennan L, et al. Elevated serum homocysteine as a predictor for vitamin B12 or folate deficiency. Eur J Haematol 1994; 52: 227-232.
186. Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47-53.
187. Ubbink JB, van der Merwe A, Vermaak WJ, et al. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest 1993; 71: 993-998.
188. Franken DG, Boers GH, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994; 14: 465-470.
189. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332: 328-329.
190. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141.
191. Friedman JA, Dwyer JT. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Nutr Rev 1996; 53: 197-201.
192. Bachmann J, Tepel M, Zidek W, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121-125.
193. Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
194. Tamura T. Bergman SM Morgan SL. Hyperhomocysteinemia as a cause of vascular occlusion in end-stage renal disease. Int J Artif Organs 1998; 21: 72-74.
195. Wilcken DE, Gupta VJ Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981; 61: 743-749.
196. Arnadottir M, Brattstrom L, Simonsen O, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-240.
197. Robinson K, Gupta A, Dennis VW, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-2748.
198. Janssen MJ, van den Berg M, van Guldener C, et al. Withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 1994; 42: 136-137.
199. Janssen MJFM, van Guldener C, de Jong GMT, et al. Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 1996; 22: 110-114.
200. Chauveau P, Chadefaux B, Coude M, et al. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996; 22: 106-109.
201. Baggott JE, Heimburger DC, Krumdieck CL, et al. Folate conjugase activity in the plasma and tumors of breast cancer patients. Am J Clin Nutr 1987; 46: 295-301.
202. Bostom AG, Shemin D, Lapane KL, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-152.
203. Hultberg B, Andersson A Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230-235.
204. Chauveau P, Chadefaux B, Coude M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 41(Suppl.): S72-7.
205. Zidek W. Homocysteine - a new arteriosclerotic risk factor in end-stage renal failure. Nephron 1997; 75: 249-250.
206. Guttormsen AB, Ueland PM, Svarstad E, et al. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 495-502.
207. Hultberg B, Andersson A Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron 1995; 70: 62-67.
208. Bostom A, Brosnan JT, Hall B, et al. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
209. Mudd SH, Finkelstein JD, Irreverre F, et al. Transsulfuration in mammals. Microassays and tissue distributions of three enzymes of the pathway. J Biol Chem 1965; 240: 4382-4392.
210. Finkelstein JD, Kyle W Harris BJ. Methionine metabolism in mammals. Regulation of homocysteine methyltransferases in rat tissue. Arch Biochem Biophys 1971; 146: 84-92.
211. Perry U, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancer 1995; 346: 1395-1398.
212. van den Berg M, Stehouwer CDA, Bierdrager E, et al. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-171.
213. Munshi MN, Stone A, Fink L, et al. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133-135.
214. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997; 20: 1880-1886.
215. Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 277-282.
216. Agardh CD, Agardh E, Andersson A, et al. Lack of association between plasma homocysteine levels and microangiopathy in type I diabetes mellitus. Scand J Clin Lab Invest 1994; 54:637-641.
217. Amadottir M, Hultberg B, Vladov V, et al. Hyperhomocysteinemia in cyclosporin-treated renal transplant recipients. Transplantation 1996; 61: 509-512.
218. Lawson MF. Homocysteine and atherothrombosis, N Engl J Med 1998; 339: 477-478.
219. Bostom AG, Gohh RY, Tsai MY, et al. Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 1997; 17: 1894-1900.
220. Ducloux D, Fournier V, Rebibou JM, et al. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Clin Nephrol 1998; 49; 232-235.
221. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 1103-1108.
222. Ambrosi P, Barlatier A, Habib G, et al. Hyperhomocysteinaemia in heart transplant recipients, Eur Heart J 1994; 15: 1191-1195.
223. Berger PB, Jones JD, Olson LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 1995; 70: 125-131.
224. Gupta A, Moustapha A, Jacobsen DW, et al. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998; 65: 544-550.
225. Pettersson T, Friman C, Abrahamsson L, et al. Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia. J Rheumatol 1998; 25: 859-863.
226. Krogh JM, Ekelund S Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest 1996; 56: 421-429.
227. Roubenoff R, Dellaripa P, Nadeau MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997; 40: 718-722.
228. Nedrebo BG, Ericsson UB, Nygard O, et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998; 47: 89-93.
229. Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124.
230. Refsum H, Wesenberg F Ueland PM. Plasma homocysteine in children with acute lympho-blastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991; 51: 828-835.
231. Refsum H, Helland S Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 1989; 46: 510-520.
232. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.
233. Ubbink JB, van der Merwe A, Delport R, et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-184.
234. Ueland P.M., Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
235. Lien EA, Anker G, Lonning PE, et al. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochem Soc Trans 1997; 25: 33-35.
236. Hultberg B, Andersson A, Masson P, et al. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest 1994; 54: 417-422.
237. Miner SES, Ross HJ, Langman LJ, et al. Total plasma homocysteine concentrations are strongly correlated with whole blood cyclosporine levels and angiographic coronary artery disease in heart transplant, patients. Transplantation 1998; 9(Suppl. 1): 103(Abstract).
238. Chung G, Walker S, Vadher B, et al. Effect of Sandimmune cyclosporine on renal blood flow and function in heart transplant recipients. Transplant Proc 1998; 30: 1147-1148.
239. McNally PG, Feehally J. Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. Nephrol Dial Transplant 1992; 7: 791-804.
240. Guttormsen AB, Ueland PM, Lonning PE, et al. Kinetics of plasma total homocystine in patients receiving high-dose methotrexate therapy. Clin Chem 1998; 44: 1987-1989.
241. Sperandeo MF, de Franchis R, Andria G, et al. A 68-bp insertion found in a homocysteinuric patient is a common variant and is skipped by alternative splicing of the cystathionine β-synthase mRNA. Am J Hum Genet 1996; 59: 1391-1393.
242. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-210.
243. Wendel U, Bremer HJ. Betaine in the treatment of homocysteinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr 1984; 142: 147-150.